These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15994133)

  • 1. Measurement of tobramycin and gentamicin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Spencer H; Kozlowska W; Davies JC; Webber P; Chadwick M; Kerr J; Makhecha S
    J Cyst Fibros; 2005 Sep; 4(3):209. PubMed ID: 15994133
    [No Abstract]   [Full Text] [Related]  

  • 2. Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
    Madsen V; Lind A; Rasmussen M; Coulthard K
    J Cyst Fibros; 2004 Dec; 3(4):249-51. PubMed ID: 15698943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis.
    Guy EL; Bosomworth M; Denton M; Conway SP; Brownlee KG; Lee TW
    J Cyst Fibros; 2010 Jul; 9(4):292-5. PubMed ID: 20427245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability of aminoglycosides pharmacokinesis in C.F. patients in relation with certain clinical parameters.
    Douchain F; Lebas L; Houdas S; Chivet C; Bakhache P; Pautard JC
    Acta Univ Carol Med (Praha); 1990; 36(1-4):37-9. PubMed ID: 2130714
    [No Abstract]   [Full Text] [Related]  

  • 6. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis.
    Alghanem S; Paterson I; Touw DJ; Thomson AH
    J Antimicrob Chemother; 2013 Jun; 68(6):1338-47. PubMed ID: 23435691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection.
    Moriarty TF; McElnay JC; Elborn JS; Tunney MM
    Pediatr Pulmonol; 2007 Nov; 42(11):1008-17. PubMed ID: 17902147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development?
    Burkhardt O; Lehmann C; Madabushi R; Kumar V; Derendorf H; Welte T
    J Antimicrob Chemother; 2006 Oct; 58(4):822-9. PubMed ID: 16885180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized aminoglycoside dosage regimens in patients with cystic fibrosis.
    Delage G; Desautels L; Legault S; Lasalle R; Lapierre JG; Lamarre A; Masson P; Spier S
    Drug Intell Clin Pharm; 1988 May; 22(5):386-9. PubMed ID: 3391108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of tobramycin levels obtained from central venous access devices in patients with cystic fibrosis is technique dependent.
    Mogayzel PJ; Pierce E; Mills J; McNeil A; Loehr K; Joplin R; McMahan S; Carson KA
    Pediatr Nurs; 2008; 34(6):464-8; quiz 468-9. PubMed ID: 19263753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
    Lam W; Tjon J; Seto W; Dekker A; Wong C; Atenafu E; Bitnun A; Waters V; Yau Y; Solomon M; Ratjen F
    J Antimicrob Chemother; 2007 Jun; 59(6):1135-40. PubMed ID: 17446242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled tobramycin-associated hearing loss in an adolescent with renal failure.
    Patatanian L
    Pediatr Infect Dis J; 2006 Mar; 25(3):276-8. PubMed ID: 16511399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis.
    Bragonier R; Brown NM
    J Antimicrob Chemother; 1998 Jul; 42(1):103-6. PubMed ID: 9700537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients.
    Roberts GW; Nation RL; Jarvinen AO; Martin AJ
    Br J Clin Pharmacol; 1993 Oct; 36(4):372-5. PubMed ID: 12959319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of therapeutic drug monitoring of digoxin and gentamicin in the saliva of children.
    Berkovitch M; Bistritzer T; Aladjem M; Burtin P; Dagan T; Chen-Levi Z; Freedom R; Koren G
    Ther Drug Monit; 1998 Jun; 20(3):253-6. PubMed ID: 9631920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations in aminoglycoside pharmacokinetics in patients with cancer.
    Higa GM; Murray WE
    Clin Pharm; 1987 Dec; 6(12):963-6. PubMed ID: 3427879
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.